Management of Rheumatologic Immune-Related Adverse Events (Rh-irAEs) – An Overview of Immunosuppressive Therapies
DOI:
https://doi.org/10.58931/crt.2024.1147Abstract
Cancer treatment has entered a new era with the expanding role of immunotherapy, in particular immune checkpoint inhibitors (ICIs). ICIs, including those that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death protein-1 (PD-1), and programmed death ligand-1 (PD-L1), work by blocking the intrinsic down-regulators of the immune system, leading to sustained activation of effector T-cells to enhance endogenous anti-tumour immune responses.
References
Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related adverse avents associated with cancer iImmunotherapy: a review for the practicing rheumatologist. J Rheumatol. 2020;47(2):166-175. doi:10.3899/jrheum.190084 DOI: https://doi.org/10.3899/jrheum.190084
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/jco.21.01440 DOI: https://doi.org/10.1200/JCO.21.01440
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, Maryland, U.S.A., 2017 [Accessed February 15, 2024, Updated November 27, 2017]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217-1238. doi:10.1016/j.annonc.2022.10.001 DOI: https://doi.org/10.1016/j.annonc.2022.10.001
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6). doi:10.1136/jitc-2021-002435 DOI: https://doi.org/10.1136/jitc-2021-002435
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36-48. doi:10.1136/annrheumdis-2020-217139 DOI: https://doi.org/10.1136/annrheumdis-2020-217139
Ye C, Jamal S, Hudson M, Fifi-Mah A, Roberts J. Immune checkpoint inhibitor associated rheumatic adverse events: a review of their presentations and treatments. Current Treatment Options in Rheumatology. 2019;5(4):272-289. doi:10.1007/s40674-019-00131-z DOI: https://doi.org/10.1007/s40674-019-00131-z
Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3). doi:10.1136/jitc-2022-006398 DOI: https://doi.org/10.1136/jitc-2022-006398
Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol. 2020;32(3):315-320. doi:10.1097/bor.0000000000000701 DOI: https://doi.org/10.1097/BOR.0000000000000701
Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, et al. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer. 2019;145(5):1408-1413. doi:10.1002/ijc.32080 DOI: https://doi.org/10.1002/ijc.32080
Wang Y, Yang M, Tao M, Liu P, Kong C, Li H, et al. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment. Int Immunopharmacol. 2021;99:108031. doi:10.1016/j.intimp.2021.108031 DOI: https://doi.org/10.1016/j.intimp.2021.108031
Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706-3714. doi:10.1002/cncr.31629 DOI: https://doi.org/10.1002/cncr.31629
Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, et al. Early use of high-dose glucocorticoid for the management of irae is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res.2021;27(21):5993-6000. doi:10.1158/1078-0432.Ccr-21-1283 DOI: https://doi.org/10.1158/1078-0432.CCR-21-1283
Gente K, Diekmann L, Daniello L, Will J, Feisst M, Olsavszky V, et al. Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events. J Immunother Cancer. 2023;11(9). doi:10.1136/jitc-2023-007557 DOI: https://doi.org/10.1136/jitc-2023-007557
Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol. 2023;7(1):41. doi:10.1038/s41698-023-00380-1 DOI: https://doi.org/10.1038/s41698-023-00380-1
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481 DOI: https://doi.org/10.1056/NEJMra1703481
Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569-579. doi:10.1038/s41584-018-0074-9 DOI: https://doi.org/10.1038/s41584-018-0074-9
Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468-475. doi:10.1002/art.40745 DOI: https://doi.org/10.1002/art.40745
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19(8):102595. doi:10.1016/j.autrev.2020.102595 DOI: https://doi.org/10.1016/j.autrev.2020.102595
Barron CC, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(8). doi:10.1136/jitc-2022-006500 DOI: https://doi.org/10.1136/jitc-2022-006500
Ladouceur A, Arreola LG, Jamal S, Hudson M, Pope J, Hoa S, et al. POS1567 Outcomes and predictors of chronic immune checkpoint inhibitor induced inflammatory arthritis: data from the Canadian Research Group of Rheumatology In Immuno-Oncology (CANRIO) retrospective cohort. Annals of the Rheumatic Diseases. 2023;82(Suppl 1):1158-1159. doi:10.1136/annrheumdis-2023-eular.1018 DOI: https://doi.org/10.1136/annrheumdis-2023-eular.1018
Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer. 2018;105:88-102. doi:10.1016/j.ejca.2018.09.027 DOI: https://doi.org/10.1016/j.ejca.2018.09.027
Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985-e994. doi:10.1212/wnl.0000000000006124 DOI: https://doi.org/10.1212/WNL.0000000000006124
Kochanek C, Gilde C, Zimmer L, Ugurel S, Meier F, Utikal J, et al. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - an analysis of the prospective skin cancer registry ADOREG. Eur J Cancer. 2024;198:113508. doi:10.1016/j.ejca.2023.113508 DOI: https://doi.org/10.1016/j.ejca.2023.113508
Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, et al. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: a real-world, multicenter, retrospective study. Cancer. 2023;129(12):1885-1894. doi:10.1002/cncr.34742 DOI: https://doi.org/10.1002/cncr.34742
Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP, et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023;82(7):920-926. doi:10.1136/ard-2023-223885 DOI: https://doi.org/10.1136/ard-2023-223885
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509-523.e506. doi:10.1016/j.ccell.2022.04.004 DOI: https://doi.org/10.1016/j.ccell.2022.04.004
Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7(6):e1438106. doi:10.1080/2162402x.2018.1438106 DOI: https://doi.org/10.1080/2162402X.2018.1438106
Wang C, Lin J, Wang Y, Hsi DH, Chen J, Liu T, et al. Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and tofacitinib treatment. Front Pharmacol. 2021;12:770631. doi:10.3389/fphar.2021.770631 DOI: https://doi.org/10.3389/fphar.2021.770631
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819-829. doi:10.1056/NEJMoa1604958 DOI: https://doi.org/10.1056/NEJMoa1604958
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi:10.1126/science.aar4060 DOI: https://doi.org/10.1126/science.aar4060
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Rheumatology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.